Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?

Clinical Endocrinology

Volumn 81, Issue 6, 2014, Pages 812-817

  Jacob, Jubbin J ^a   Bevan, John S ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; ANGIOPEPTIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOPEPTIDE; SOMATOSTATIN;

ACROMEGALY; ADENOHYPOPHYSIS; ADENOMA; ANESTHESIA LEVEL; ARTERIAL STIFFNESS; ARTICLE; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; HYPOPHYSIS DISEASE; INTUBATION; LENGTH OF STAY; META ANALYSIS (TOPIC); MICROADENOMA; NEUROHYPOPHYSIS; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TUMOR REGRESSION; URINE; ADJUVANT THERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ENDOTRACHEAL INTUBATION; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; INTRAOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROCEDURES; TIME;

ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INTRAOPERATIVE COMPLICATIONS; INTUBATION, INTRATRACHEAL; NEOADJUVANT THERAPY; OCTREOTIDE; PEPTIDES, CYCLIC; PREOPERATIVE CARE; SOMATOSTATIN; TIME FACTORS;

EID: 84912096390     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12553     Document Type: Article

References (27)

1. Nomikos, P., Buchfelder, M., &, Fahlbusch, R., (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology, 152, 379-387.
2. Lissett, C.A., Peacey, S.R., Laing, I., et al,. (1998) The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical Endocrinology (Oxf), 49, 653-657.
3. Bates, P.R., Carson, M.N., Trainer, P.J., et al,. (2008) Wide variation in surgical outcomes for acromegaly in the UK. Clinical Endocrinology (Oxf), 68, 136-142.
4. Bevan, J.S., (2005) Clinical review: the anti-tumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1856-1863.
5. Caron, P.J., Bevan, J.S., Petersenn, S., et al,. (2014) Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. Journal of Clinical Endocrinology and Metabolism, 99, 1282-1290.
6. Ben-Shlomo, A., &, Melmed, S., (2003) Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 88, 963-968.
7. Melmed, S., Colao, A., Barkan, A., et al,. (2009) Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism, 94, 1509-1517.
8. Pita-Gutierrez, F., Pertega-Diaz, S., Pita-Fernandez, S., et al,. (2013) Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS ONE, 8, e61523.
9. Carlsen, S.M., Lund-Johansen, M., Schreiner, T., et al,. (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism, 93, 2984-2990.
10. Mao, Z.G., Zhu, Y.H., Tang, H.L., et al,. (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. European Journal of Endocrinology, 162, 661-666.
11. Shen, M., Shou, X., Wang, Y., et al,. (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocrine Journal, 57, 1035-1044.
12. Li, Z.Q., Quan, Z., Tian, H.L., et al,. (2012) Preoperative Lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. Journal of International Medical Research, 40, 517-524.
13. Kristof, R.A., Stoffel-Wagner, B., Klingmuller, D., et al,. (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochirurgica (Wien), 141, 399-405.
14. Biermasz, N.R., van Dulken, H., Roelfsema, F., et al,. (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. Journal of Clinical Endocrinology and Metabolism, 84, 3551-3555.
15. Colao, A., Ferone, D., Cappabianca, P., et al,. (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism, 82, 3308-3314.
16. Abe, T., &, Ludecke, D.K., (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. European Journal of Endocrinology, 145, 137-145.
17. Plockinger, U., &, Quabbe, H.J., (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochirurgica (Wien), 147, 485-493.
18. Losa, M., Mortini, P., Urbaz, L., et al,. (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. Journal of Neurosurgery, 104, 899-906.
19. Stevenaert, A., &, Beckers, A., (1996) Presurgical Octreotide: treatment in acromegaly. Metabolism, 45, 72-74.
20. Stevenaert, A., Harris, A.G., Kovacs, K., et al,. (1992) Presurgical octreotide treatment in acromegaly. Metabolism, 41, 51-58.
21. Seidman, P.A., Kofke, W.A., Policare, R., et al,. (2000) Anesthetic complications in acromegaly. British Journal of Anaesthesia, 84, 179-182.
22. Annamalai, A.K., Webb, A., Kandasamy, N., et al,. (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. Journal of Clinical Endocrinology and Metabolism, 98, 1040-1050.
23. Tolis, G., Angelopoulos, N.G., Katounda, E., et al,. (2006) Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology, 83, 249-257.
24. Swearingen, B., Barker, F.G., Katznelson, L., et al,. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
25. Freda, P.U., Wardlaw, S.L., &, Post, K.D., (1998) Long-term endocrinologic follow-up after transsphenoidal surgery for acromegaly. Journal of Neurosurgery, 89, 353-358.
26. Giustina, A., Barkan, A., Casanueva, F.F., et al,. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526-529.
27. Giustina, A., Chanson, P., Bronstein, M.D., et al,. (2010) A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism, 95, 3141-3148.